HEB Key Stats
|Revenue (Quarterly YoY Growth)||-7.69%|
|EPS Diluted (TTM)||-0.1152|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-18.49M|
|Gross Profit Margin (Quarterly)||-600.0%|
|Profit Margin (Quarterly)||-14267%|
|Dividend Yield (TTM)||0.00%|
|Payout Ratio (TTM) Pro||Go Pro|
- HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi Dec 6
- Hemispherx Biopharma Appoints New Chief Financial and Chief Accounting Officers …..Seasoned Executives in Financial and Accounting Matters with International Experience noodls Dec 4
- Hemispherx Biopharma Appoints New Chief Financial and Chief Accounting Officers GlobeNewswire Dec 4
- Hemispherx Biopharma and the University of Pittsburgh Collaborate on a Novel Chemokine-Modulatory Program for Cancer Immunotherapies with Ampligen® as a Key Component noodls Dec 2
- Hemispherx Biopharma and the University of Pittsburgh Collaborate on a Novel Chemokine-Modulatory Program for Cancer Immunotherapies With Ampligen(R) as a Key Component GlobeNewswire Dec 2
- HEMISPHERX BIOPHARMA SPONSORS CHRONIC FATIGUE SYNDROME CONFERENCE AT MOUNT SINAI MEDICAL CENTER IN NEW YORK noodls Nov 19
- Hemispherx Biopharma (HEB) CFO Resigns Street Insider Nov 18
- HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers Nov 18
- Hemispherx Biopharma (HEB) Posts Q3 Loss of 3c/Share Street Insider Nov 11
- Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2013 GlobeNewswire Nov 8
HEB Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Hemispherx Biopharma is down 75.06% over the last year vs S&P 500 Total Return up 30.43%, Geron up 418.6%, and Neostem up 1.28%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for HEB
Pro Strategies Featuring HEB
Did Hemispherx Biopharma make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Hemispherx Biopharma, Inc. is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.